Cover Image

Partnerships, Licensing, Investments and M&A Deals and Trends for February 2014 in Pharmaceuticals

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for February 2014 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in February 2014. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals deals database and primary and secondary research.

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the six months.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 6
  • 1.2 List of Figures 9

2 Pharmaceuticals & Healthcare, Global, Deal Summary 12

  • 2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, February 2014 12
  • 2.2 Pharmaceuticals & Healthcare, Global, Major Deals, February 2014 14
    • 2.2.1 Actavis to Acquire Forest Labs for US$25 Billion 14
    • 2.2.2 Merck Enters into Licensing Agreement with Ablynx for Cancer Immunotherapy 15
    • 2.2.3 Medtronic Completes Public Offering of Notes for US$2 Billion 15
    • 2.2.4 Smith & Nephew Receives Regulatory Approval to Acquire ArthroCare for US$1.7 Billion 15
    • 2.2.5 Mallinckrodt Completes Acquisition of Cadence Pharma for US$1.4 Billion in Tender Offer 17
  • 2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, February 2014 19
  • 2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, February 2014 20

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 21

  • 3.1 Pharmaceuticals & Healthcare, Global, M&A, February 2014 21
    • 3.1.1 Top M&A Deals in February 2014 22
    • 3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, September 2013 - February 2014 23
  • 3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, February 2014 25
    • 3.2.1 Top Equity Offering Deals in February 2014 26
    • 3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, September 2013 - February 2014 27
  • 3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, February 2014 28
    • 3.3.1 Top PE/VC Deals in February 2014 29
    • 3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, February 2014 30
    • 3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, February 2014 31
    • 3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, September 2013-February 2014 33
    • 3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, September 2013-February 2014 34

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, February 2014 35

  • 4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, February 2014 35
  • 4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, September 2013 - February 2014 37
  • 4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), February 2014 38
    • 4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, February 2014 39
  • 4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), September 2013 - February 2014 40
  • 4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, September 2013 - February 2014 42
  • 4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), September 2013 - February 2014 43
  • 4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), September 2013 - February 2014 45

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, February 2014 47

  • 5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, February 2014 47
  • 5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), February 2014 49
    • 5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, February 2014 50
    • 5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, February 2014 51
    • 5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, February 2014 51
  • 5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), September 2013 - February 2014 52
  • 5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), September 2013 - February 2014 54
  • 5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), September 2013 - February 2014 56
  • 5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), September 2013 - February 2014 58

6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 60

  • 6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, February 2014 60
    • 6.1.1 Oncology - Deals of the Month 61
  • 6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, February 2014 63
    • 6.2.1 Central Nervous System - Deals of the Month 64
  • 6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, February 2014 66
    • 6.3.1 Infectious Diseases - Deals of the Month 67
  • 6.4 Pharmaceuticals & Healthcare, Global, Metabolic Disorder Deals, February 2014 69
    • 6.4.1 Metabolic Disorders - Deal of the Month 70
  • 6.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, February 2014 72
    • 6.5.1 Immunology - Deal of the Month 73
  • 6.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, February 2014 75
    • 6.6.1 Cardiovascular - Deal of the Month 76
  • 6.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals, February 2014 77
    • 6.7.1 Gastrointestinal - Deals of the Month 78

7 Deal Summary by Geography 80

  • 7.1 Pharmaceuticals & Healthcare, North America Deals, February 2014 80
    • 7.1.1 North America - Deals of the Month 81
  • 7.2 Pharmaceuticals & Healthcare, Europe, Deals, February 2014 86
    • 7.2.1 Europe - Deals of the Month 87
  • 7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, February 2014 89
    • 7.3.1 Asia-Pacific - Deals of the Month 90
  • 7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, February 2014 92
    • 7.4.1 Rest of the World - Deals of the Month 93

8 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 95

  • 8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, September 2013 - February 2014 95
  • 8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, September 2013 - February 2014 97

9 Further Information 99

  • 9.1 Methodology 99
  • 9.2 About GlobalData 100
  • 9.3 Disclosure information 101
  • 9.4 Disclaimer 101

1.1 List of Tables

  • Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 13
  • Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, February 2014 14
  • Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), February 2014 20
  • Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 22
  • Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, February 2014 22
  • Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, September 2013 - February 2014 24
  • Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 26
  • Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, February 2014 26
  • Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 27
  • Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 29
  • Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, February 2014 29
  • Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, September 2013 - February 2014 31
  • Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), February 2014 33
  • Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 34
  • Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, September 2013 - February 2014 34
  • Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 36
  • Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 37
  • Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2013 - February 2014 38
  • Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), February 2014 39
  • Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), September 2013 - February 2014 41
  • Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2013 - February 2014 44
  • Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), September 2013 - February 2014 46
  • Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 48
  • Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), September 2013 - February 2014 50
  • Table 25: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, February 2014 50
  • Table 26: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, February 2014 51
  • Table 27: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, February 2014 51
  • Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 53
  • Table 29: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), February 2014 55
  • Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2013 - February 2014 57
  • Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), February 2014 59
  • Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 61
  • Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 64
  • Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 67
  • Table 35: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 70
  • Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 73
  • Table 37: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 76
  • Table 38: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 78
  • Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 81
  • Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 87
  • Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 90
  • Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 93
  • Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 96
  • Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 98

1.2 List of Figures

  • Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 12
  • Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), February 2014 19
  • Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), February 2014 20
  • Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 21
  • Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, September 2013 - February 2014 23
  • Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 25
  • Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 27
  • Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 28
  • Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, September 2013 - February 2014 30
  • Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), February 2014 31
  • Figure 11:Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), February 2014 32
  • Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 33
  • Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 35
  • Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 37
  • Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2013 - February 2014 38
  • Figure 16:Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), September 2013 - February 2014 40
  • Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2013 - February 2014 42
  • Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2013 - February 2014 43
  • Figure 19:Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), September 2013 - February 2014 45
  • Figure 20:Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 47
  • Figure 21:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2013 - February 2014 49
  • Figure 22:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 52
  • Figure 23:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), September 2013 - February 2014 54
  • Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, September 2013 - February 2014 56
  • Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), September 2013 - February 2014 57
  • Figure 26:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), February 2014 58
  • Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 60
  • Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 63
  • Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 66
  • Figure 30: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 69
  • Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 72
  • Figure 32: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 75
  • Figure 33: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 77
  • Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 80
  • Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 86
  • Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 89
  • Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 92
  • Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 95
  • Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), September 2013 - February 2014 97
Show More
Pricing
Get Notified
Email me when related reports are published